Alexion Pharma (ALXN) Tops Q2 EPS by 5c; Updates FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Alexion Pharmaceuticals (ALXN) PT Raised to $221 at Brean Capital Amid 'Strong' Q2
July 31, 2015 7:58 AM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $221.00 (from $213.00) following "strong" Q2 results despite FX headwinds.
Aschoff commented, "Alexion reported 2Q15 Soliris revenue of $636 million, beating consensus of $630 million despite strong FX headwinds. Diluted non-GAAP EPS of $1.44 beat consensus of $1.37. Revenue guidance for 2015 increased from the previous range of $2.55-2.6 billion to $2.6-2.62 billion, including a 6%... More
